FDA approves Gilead Sciences’ Epclusa for chronic HCV: 4 observations

The FDA has approved Gilead Sciences’ Epclusa to treat adults with chronic hepatitis C, both with and without cirrhosis.

Advertisement

Here are four observations:

1.  Epclusa is a fixed-dose combination tablet.

2. The drug is approved for use in combination with ribavirin for patients with moderate to severe cirrhosis.

3. Epclusa’s most common side effects are headache and fatigue.

4. Gilead Sciences has courted controversy in the past. The company’s Sovaldi and Harvoni drugs, also intended for HCV treatment, were criticized for their high prices.

More articles on GI/endoscopy:
4 key trends in the $2.35B GI/endoscopic devices market
Merit Health Natchez adds Dr. W. Kirk Mullins: 4 points
5 most read GI/endoscopy stories: June 20 — June 24

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

  • Premier Health Partners has acquired Dayton, Ohio-based Digestive Specialists, according to a notice posted on the website of law firm…

Advertisement

Comments are closed.